Illumina's Grail to offer cancer detection blood test to patients in Utah
Illumina's (NASDAQ:ILMN) subsidiary Grail said on Tuesday it will offer its multi-cancer early detection blood test, Galleri, to eligible patients in Utah.
The test will also be available to eligible employees and their families who are enrolled in a company-sponsored health plan, Grail said.

In a clinical study, the Galleri test was able to detect signals across more than 50 types of cancer, more than 45 of which lack recommended screening tests, with a low false positive rate of less than 1%.
The test will be available to patients at elevated risk for cancer, such as adults over 50 years old or with additional risk factors.
The test will be offered by Grail's partner healthcare provider Intermountain.
ILMN stock rose 2.7% before the bell.